drugset / Trial / NCT00235950

Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease

NCT00235950

Phase 4 Completed 255 enrolled AstraZeneca
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of treatment in patients with coronary heart disease

Timeline

Start
2004-01
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg
Subject Atorvastatin Small molecule 80 mg
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 40 mg
Background Clopidogrel Small molecule
Background Simvastatin Small molecule